Healthcare [ 3/11 ] | Drug Manufacturers—General [ 136/154 ]
US | NYSE | Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
Oct 28, 22 | 3.66
Increased by
+9.91%
|
3.57
Increased by
+2.52%
|
Jul 29, 22 | 3.37
Increased by
+8.36%
|
3.31
Increased by
+1.81%
|
Apr 29, 22 | 3.16
Increased by
+7.12%
|
3.14
Increased by
+0.64%
|
Feb 2, 22 | 3.31
Increased by
+13.36%
|
3.29
Increased by
+0.61%
|
Oct 29, 21 | 3.33
Increased by
+17.67%
|
3.22
Increased by
+3.42%
|
Jul 30, 21 | 3.11
Increased by
+32.91%
|
3.09
Increased by
+0.65%
|
Apr 30, 21 | 2.95
Increased by
+21.90%
|
2.83
Increased by
+4.24%
|
Feb 3, 21 | 2.92
Increased by
+32.13%
|
2.85
Increased by
+2.46%
|
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Sep 30, 22 | 14.81 B
Increased by
+3.28%
|
3.95 B
Increased by
+24.22%
|
Increased by
+26.66%
Increased by
+20.28%
|
Jun 30, 22 | 14.58 B
Increased by
+4.47%
|
924.00 M
Increased by
+20.63%
|
Increased by
+6.34%
Increased by
+15.47%
|
Mar 31, 22 | 13.54 B
Increased by
+4.06%
|
4.49 B
Increased by
+26.37%
|
Increased by
+33.17%
Increased by
+21.44%
|
Dec 31, 21 | 14.89 B
Increased by
+7.42%
|
4.04 B
Increased by
+11.13 K%
|
Increased by
+27.17%
Increased by
+10.36 K%
|
Sep 30, 21 | 14.34 B
Increased by
+11.16%
|
3.18 B
Increased by
+37.74%
|
Increased by
+22.17%
Increased by
+23.91%
|
Jun 30, 21 | 13.96 B
Increased by
+33.90%
|
766.00 M
Increased by
+203.79%
|
Increased by
+5.49%
Increased by
+177.52%
|
Mar 31, 21 | 13.01 B
Increased by
+50.95%
|
3.55 B
Increased by
+18.04%
|
Increased by
+27.31%
Decreased by
-21.80%
|
Dec 31, 20 | 13.86 B
Increased by
+59.21%
|
36.00 M
Decreased by
-98.71%
|
Increased by
+0.26%
Decreased by
-99.19%
|
Rank | ETF | Shares | Market Value | Weight % in ETF |
---|
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.